Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in lung fibrosis

Author(s):  
Andrea Schamberger ◽  
Herbert Schiller ◽  
Isis Fernandez ◽  
Martina Sterclova ◽  
Katharina Heinzelmann ◽  
...  
2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Andrea C. Schamberger ◽  
Herbert B. Schiller ◽  
Isis E. Fernandez ◽  
Martina Sterclova ◽  
Katharina Heinzelmann ◽  
...  

1996 ◽  
Vol 270 (2) ◽  
pp. L173-L182 ◽  
Author(s):  
N. Avissar ◽  
J. N. Finkelstein ◽  
S. Horowitz ◽  
J. C. Willey ◽  
E. Coy ◽  
...  

The epithelial cells of the lower respiratory tract are exposed to high levels of inhaled oxygen and other oxidants. We hypothesized that lung cells would secrete the antioxidant enzyme, extracellular glutathione peroxidase (eGPx), into epithelial lining fluid (ELF). To investigate this hypothesis, we used specific immunoprecipitations of GPx enzymes from ELF, specific immunoprecipitations of 75Se metabolically labeled proteins from lung cells in culture, and in situ hybridization, Northern blot, and reverse transcription-polymerase chain reaction (RT-PCR) analyses. Fifty-seven percent of ELF GPx activity was due to eGPx and 40% was due to cellular GPx (cGPx). Primary bronchial epithelial cells (BEC), primary alveolar macrophages (AM), and two human bronchial epithelial cell lines, BEP2D and A549, synthesized both eGPx and cGPx and secreted eGPx into the medium. Freshly isolated human AM and BEC expressed eGPx mRNA, while freshly isolated rabbit type 2 pneumocytes did not. In lung tissue, eGPx mRNA was found mainly in interstitial cells of tissue surrounding airways. It is concluded that more than half of GPx activity in BAL is due to eGPx, and that BEC, AM, and interstitial cells are potential sources of pulmonary eGPx.


PLoS ONE ◽  
2012 ◽  
Vol 7 (10) ◽  
pp. e46214 ◽  
Author(s):  
Dun-Fa Peng ◽  
Tian-Ling Hu ◽  
Barbara G. Schneider ◽  
Zheng Chen ◽  
Ze-Kuan Xu ◽  
...  

2004 ◽  
Vol 48 (4) ◽  
pp. 1215-1221 ◽  
Author(s):  
Naomi R. Florea ◽  
Pamela R. Tessier ◽  
Cuilian Zhang ◽  
Charles H. Nightingale ◽  
David P. Nicolau

ABSTRACT Recent clinical failures associated with levofloxacin treatment for Streptococcus pneumoniae infections and growing evidence of frequent mutations in the isolate population have led to increased concerns regarding fluoroquinolone resistance. Our objective was to characterize the efficacies of levofloxacin and moxifloxacin against various genotypes of S. pneumoniae after simulated bronchopulmonary exposures. An in vitro model was used to simulate a levofloxacin concentration of 500 mg and a moxifloxacin concentration of 400 mg, which were previously determined to be the concentrations in the epithelial lining fluid of older adults receiving once-daily dosing. The effects of the drugs were tested against six S. pneumoniae containing various mutations. Bacterial density and resistance were quantitatively assessed over 48 h. The S. pneumoniae isolate with no mutation displayed a 4-log reduction in CFU after treatment with both agents and did not develop resistance. Isolates containing the parC or parE mutation or both mutations regrew and developed resistance when they were exposed to levofloxacin, despite an unbound area under the concentration-time curve (AUC):MIC ratio of ∼100. When the isolate containing the parC and gyrA mutations was exposed to levofloxacin, there was a half-log reduction in the number of CFU compared to that for the control, but the isolate subsequently regrew. Likewise, levofloxacin did not kill the isolate containing the parC, gyrA, and parE mutations. Moxifloxacin sustained the killing of all bacterial isolates tested without the development of resistance. Levofloxacin did not sustain bacterial killing and did not prevent the emergence of further resistance in mutants with the parC or parE mutation or both mutations, even though an unbound AUC:MIC ratio for exposure well above the breakpoint of 30 to 40 established in the literature for S. pneumoniae was maintained. Moxifloxacin was effective against all isolates tested, despite the presence of isolates with two- and three-step mutations, for which the MICs were increased.


2016 ◽  
Vol 60 (8) ◽  
pp. 5085-5087 ◽  
Author(s):  
Danilo Cesar Galindo Bedor ◽  
Sandrine Marchand ◽  
Isabelle Lamarche ◽  
Julian Laroche ◽  
Davi Pereira de Santana ◽  
...  

ABSTRACTThe aim of this study was to determine the biopharmaceutical characteristics of oseltamivir carboxylate (OC) after pulmonary delivery. After OC bolus and intratracheal nebulization (NEB) in rats, blood was collected and bronchoalveolar lavages (BALs) were performed. Epithelial lining fluid (ELF) concentrations were estimated from BAL fluid. The area under the curve (AUC) ratio for ELF to plasma was 842 times higher after NEB than after intravenous (i.v.) administration, indicating that OC nebulization offers a biopharmaceutical advantage over i.v. administration.


Respirology ◽  
2007 ◽  
Vol 12 (5) ◽  
pp. 740-743 ◽  
Author(s):  
Yasushi NAKANO ◽  
Sadatomo TASAKA ◽  
Fumitake SAITO ◽  
Wakako YAMADA ◽  
Yoshiki SHIRAISHI ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document